NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 12 April 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Iftab Akram Present for all items
4. Michael Chambers Present for all items
5. Dr Mark Corbett Present for all items
6. Dr Prithwiraj Das Present for all items
7. Chamkhor Dhillon Present for all items
8. Dr David Foreman Items 1 to 5.1.3
9. Dr Pedro Saramago Goncalves Present for all items
10. Dr Nigel Langford Present for all items
11. Dr Steven Lloyd Present for all items
12. Iain McGowan Present for all items
13. Ugochi Nwulu Present for all items
14. Stella O’Brien Present for all items
15. Dr Clare Offer Present for all items
16. Dr Kate Ren Present for all items
17. Dr Arpit Srivastava Present for all items
18. Professor Matthew Stevenson Present for all items
19. Dr Britta Stordal Present for all items

NICE staff (key players) present

Linda Landells, Associate Director Items 1 to 4.2.2

Jasdeep Hayre, Associate Director Items 5 to 5.2.2

Louise Jafferally, Project Manager Items 1 to 4.1.3

Kate Moore, Project Manager Present for all items

Sally Doss, Heath Technology Assessment Adviser Items 1 to 4.2.2

Christian Griffiths, Heath Technology Assessment Adviser Items 5 to 5.2.2

Luke Cowie, Heath Technology Assessment Analyst Items 1 to 4.2.2

George J. Millington, Heath Technology Assessment Analyst Items 5 to 5.2.2

Raphael Egbu, Heath Technology Assessment Analyst Items 5 to 5.2.2

External assessment group representatives present

Jo Lord, Southampton Health Technology Assessment Centre (SHTAC), Items 1 to 4.1.3

Geoff Frampton, Southampton Health Technology Assessment Centre (SHTAC), Items 4 to 4.1.3

Steve Edwards, BMJ Group Items 5 to 5.1.3

Nicole Downes, BMJ Group Items 5 to 5.1.3

Archie Walters, BMJ Group Items 5 to 5.1.3

Alex Allen, BMJ Group Items 5 to 5.1.3

Clinical, Patient & NHS England experts present

Dr Sanjeev Patel, Innovative Medicines Fund Clinical lead, NHS England, Items 1 to 4.2.2

Joel Rose, Chief Executive, Cardiomyopathy UK, patient expert nominated by Cardiomyopathy UK, Items 1 to 4.1.3

Dr Sunil Nair, Consultant Cardiologist & Lead for inherited and acquired heart muscle diseases, clinical expert nominated by Norfolk & Norwich University Hospital, Items 1 to 4.1.3

Dr Lisa Anderson, Consultant Cardiologist and Chair Elect British Society for Heart Failure, clinical expert nominated by British Society for Heart Failure, Items 5 to 5.1.3

Nick Hartshorne-Evans, CEO of Pumping Marvellous Foundation, patient expert nominated by Pumping Marvellous Foundation, Items 5 to 5.1.3

Sarah Worsnop, Patient expert nominated by Pumping Marvellous Foundation, Items 5 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions*

## Minutes

### Introduction to the meeting

* 1. The chair Professor Stephen O’Brien welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Dr Alex Cale, Professor Andrew Renehan, Iftab Akram, John Hampson and Dr Rob Forsyth.

### News and announcements

* 1. Committee welcomed two new members Dr Clare Offer and Dr Kate Ren and noted many thanks and farewell to Professor Paul Tappenden who leaves committee this month.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 14 March.

### Appraisal of mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID3928]

* 1. Part 1 – Closed session - The Committee for Medicinal Products for Human Use (CHMP) has not yet given its regulatory opinion for this appraisal and therefore this discussion will take place in a part 2 session (part 2 sessions are closed to public observers).
     1. The chair welcomed the invited experts, external assessment group representatives, and company representatives from Bristol-Myers Squibb.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, here. <https://www.nice.org.uk/guidance/indevelopment/gid-ta10824/documents>
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Prithwiraj Das, and Ugochi Nwulu.
  1. Part 2 – Closed session (company representatives, clinical and patient experts and external assessment group representatives were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10824>

### Appraisal of dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction [ID1648] & empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction [ID3945]

* 1. Part 1 – Open session
     1. The chair Professor Stephen O’Brien welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Boehringer Ingelheim and AstraZeneca.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Declarations for these appraisals can be found on the Topic Register of Interest (TROI) on the topic webpages, here.

**ID1648** <https://www.nice.org.uk/guidance/indevelopment/gid-ta10942/documents>

I**D3945** <https://www.nice.org.uk/guidance/indevelopment/gid-ta10942/documents>

* + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: **ID1648** <https://www.nice.org.uk/guidance/indevelopment/gid-ta10942> **ID3945** <https://www.nice.org.uk/guidance/indevelopment/gid-ta10946>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 9 May 2023 and will start promptly at 09:30.